FLT3 Ligand (CDX-301), CD40 Agonist Antibody (CDX-1140), and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial
Latest Information Update: 19 Jul 2023
At a glance
- Drugs CDX 1140 (Primary) ; CDX 301 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Jun 2023 Status changed from recruiting to discontinued.
- 18 Jul 2022 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
- 18 Jul 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.